Roehrig John T, Hombach Joachim, Barrett Alan D T
National Center for Zoonotic, Vector-Borne and Enteric Diseases, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Fort Collins, Colorado, USA
Viral Immunol. 2008 Jun;21(2):123-32. doi: 10.1089/vim.2008.0007.
Through the Advisory Committee on Dengue and other Flavivirus Vaccines, the World Health Organization(WHO) has had a long-standing commitment to facilitate and to guide research and development of vaccines for medically important flaviviruses. Recently, the Paediatric Dengue Vaccine Initiative (PDVI) was formed to accelerate the development, testing, and introduction of dengue (DEN)vaccines worldwide, partnering with WHO in this important public health effort. There are now a variety of DEN vaccines in various stages of the developmental pipeline. In an attempt to make interlaboratory information more directly comparable, WHO with the support of PDVI initiated a program to coordinate the procedures used for the plaque-reduction neutralization test (PRNT). ThePRNT is the most common assay used to measure neutralizing antibody. The presence of antibody is believed to be most relevant means of determining protective anti-DEN virus (DENV) immunity. While other neutralizing antibody assays are being considered for use in large-scale vaccine field trials, the PRNT is still considered to be the laboratory standard against which other neutralizing antibody assays should be compared. The need for PRNT coordination has been identified at several consultations between the WHO and PDVI. A more complete version of these guidelines is available on the WHO website: http://www.who.int/immunization/documents/date/en/index.html.
通过登革热和其他黄病毒疫苗咨询委员会，世界卫生组织（WHO）长期致力于推动和指导针对具有重要医学意义的黄病毒的疫苗研发。最近，成立了儿科登革热疫苗倡议组织（PDVI），以加速登革热（DEN）疫苗在全球的开发、测试和推广，并在这项重要的公共卫生工作中与WHO合作。目前有多种处于不同研发阶段的登革热疫苗。为了使实验室间的信息更具直接可比性，WHO在PDVI的支持下启动了一项计划，以协调用于空斑减少中和试验（PRNT）的程序。PRNT是用于测量中和抗体的最常用检测方法。抗体的存在被认为是确定保护性抗登革热病毒（DENV）免疫力的最相关手段。虽然正在考虑在大规模疫苗现场试验中使用其他中和抗体检测方法，但PRNT仍被视为其他中和抗体检测方法应与之比较的实验室标准。WHO和PDVI在几次磋商中已确定了协调PRNT的必要性。这些指南的更完整版本可在WHO网站上获取：http://www.who.int/immunization/documents/date/en/index.html。
